Your browser doesn't support javascript.
loading
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada, Koutaroh; Araki, Mitsugu; Sakashita, Takuya; Ma, Biao; Kanada, Ryo; Yanagitani, Noriko; Horiike, Atsushi; Koike, Sumie; Oh-Hara, Tomoko; Watanabe, Kana; Tamai, Keiichi; Maemondo, Makoto; Nishio, Makoto; Ishikawa, Takeshi; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei.
Afiliação
  • Okada K; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Araki M; RIKEN Advanced Institute for Computational Science, 7-1-26 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
  • Sakashita T; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ma B; Research and Development Group for In Silico Drug Discovery, Pro-Cluster Kobe, Foundation for Biomedical Research and Innovation (FBRI), 6-3-5, Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
  • Kanada R; RIKEN Compass to Healthy Life Research Complex Program, 6-3-5, Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
  • Yanagitani N; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Horiike A; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Koike S; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Oh-Hara T; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Watanabe K; Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan.
  • Tamai K; Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Miyagi, Japan.
  • Maemondo M; Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan.
  • Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ishikawa T; Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
  • Okuno Y; RIKEN Advanced Institute for Computational Science, 7-1-26 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
  • Fujita N; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Katayama R; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: ryohei.katayama@jfcr.or.jp.
EBioMedicine ; 41: 105-119, 2019 Mar.
Article em En | MEDLINE | ID: mdl-30662002
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Mutação de Sentido Incorreto / Inibidores de Proteínas Quinases / Simulação de Dinâmica Molecular / Quinase do Linfoma Anaplásico / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Mutação de Sentido Incorreto / Inibidores de Proteínas Quinases / Simulação de Dinâmica Molecular / Quinase do Linfoma Anaplásico / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article